339 related articles for article (PubMed ID: 35665903)
1. MALAT1 lncRNA and Parkinson's Disease: The role in the Pathophysiology and Significance for Diagnostic and Therapeutic Approaches.
Abrishamdar M; Jalali MS; Rashno M
Mol Neurobiol; 2022 Sep; 59(9):5253-5262. PubMed ID: 35665903
[TBL] [Abstract][Full Text] [Related]
2. Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression.
Zhang QS; Wang ZH; Zhang JL; Duan YL; Li GF; Zheng DL
Biomed Pharmacother; 2016 Oct; 83():153-159. PubMed ID: 27470562
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the role of non-coding RNAs in the pathophysiology of Parkinson's disease.
Rezaei O; Nateghinia S; Estiar MA; Taheri M; Ghafouri-Fard S
Eur J Pharmacol; 2021 Apr; 896():173914. PubMed ID: 33508286
[TBL] [Abstract][Full Text] [Related]
4. Long Non-coding RNAs in Parkinson's Disease.
Xin C; Liu J
Neurochem Res; 2021 May; 46(5):1031-1042. PubMed ID: 33544326
[TBL] [Abstract][Full Text] [Related]
5. Administration of resveratrol improved Parkinson's disease-like phenotype by suppressing apoptosis of neurons via modulating the MALAT1/miR-129/SNCA signaling pathway.
Xia D; Sui R; Zhang Z
J Cell Biochem; 2019 Apr; 120(4):4942-4951. PubMed ID: 30260025
[TBL] [Abstract][Full Text] [Related]
6. MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson's disease progression.
Geng X; Li S; Li J; Qi R; Zhong L; Yu H
Mol Biol Rep; 2023 Nov; 50(11):8889-8899. PubMed ID: 37688681
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into the role of circular RNAs in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases.
Dorostgou Z; Yadegar N; Dorostgou Z; Khorvash F; Vakili O
J Neurosci Res; 2022 Sep; 100(9):1775-1790. PubMed ID: 35642104
[TBL] [Abstract][Full Text] [Related]
8. Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.
Giri B; Seamon M; Banerjee A; Chauhan S; Purohit S; Morgan J; Baban B; Wakade C
Metab Brain Dis; 2022 Aug; 37(6):1687-1696. PubMed ID: 33881722
[TBL] [Abstract][Full Text] [Related]
9. Microarray analysis of an synthetic α-synuclein induced cellular model reveals the expression profile of long non-coding RNA in Parkinson's disease.
Lin D; Liang Y; Jing X; Chen Y; Lei M; Zeng Z; Zhou T; Wu X; Peng S; Zheng D; Huang K; Yang L; Xiao S; Liu J; Tao E
Brain Res; 2018 Jan; 1678():384-396. PubMed ID: 29137975
[TBL] [Abstract][Full Text] [Related]
10. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
11. LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson's disease.
Cai LJ; Tu L; Huang XM; Huang J; Qiu N; Xie GH; Liao JX; Du W; Zhang YY; Tian JY
Mol Brain; 2020 Sep; 13(1):130. PubMed ID: 32972446
[TBL] [Abstract][Full Text] [Related]
12. The understanding of Parkinson's disease through genetics and new therapies.
Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
[TBL] [Abstract][Full Text] [Related]
13. Expression signatures of long non-coding RNA in the substantia nigra of pre-symptomatic mouse model of Parkinson's disease.
Jiao F; Wang Q; Zhang P; Bu L; Yan J; Tian B
Behav Brain Res; 2017 Jul; 331():123-130. PubMed ID: 28476570
[TBL] [Abstract][Full Text] [Related]
14. The central theme of Parkinson's disease: α-synuclein.
Ozansoy M; Başak AN
Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
[TBL] [Abstract][Full Text] [Related]
15. LncRNA HOTAIR promotes α-synuclein aggregation and apoptosis of SH-SY5Y cells by regulating miR-221-3p in Parkinson's disease.
Sun Q; Zhang Y; Wang S; Yang F; Cai H; Xing Y; Zhou L; Chen S; Wang Y
Exp Cell Res; 2022 Aug; 417(1):113132. PubMed ID: 35398161
[TBL] [Abstract][Full Text] [Related]
16. Key Non-coding Variants in Three Neuroapoptosis and Neuroinflammation-Related LncRNAs Are Protectively Associated with Susceptibility to Parkinson's Disease and Some of Its Clinical Features.
Shadkam R; Saadat P; Azadmehr A; Chehrazi M; Daraei A
Mol Neurobiol; 2024 May; 61(5):2854-2865. PubMed ID: 37946005
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease: Autoimmunity and neuroinflammation.
De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA MALAT1 regulates cell proliferation and apoptosis via miR-135b-5p/GPNMB axis in Parkinson's disease cell model.
Lv K; Liu Y; Zheng Y; Dai S; Yin P; Miao H
Biol Res; 2021 Mar; 54(1):10. PubMed ID: 33726823
[TBL] [Abstract][Full Text] [Related]
19. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
[TBL] [Abstract][Full Text] [Related]
20. miRNA in Parkinson's disease: From pathogenesis to theranostic approaches.
Elangovan A; Venkatesan D; Selvaraj P; Pasha MY; Babu HWS; Iyer M; Narayanasamy A; Subramaniam MD; Valsala Gopalakrishnan A; Kumar NS; Vellingiri B
J Cell Physiol; 2023 Feb; 238(2):329-354. PubMed ID: 36502506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
